Literature DB >> 29528378

Association of sporadic and familial Barrett's esophagus with breast cancer.

M Q Chan1, A E Blum1,2, A K Chandar1, A M L Kieber Emmons1, Y Shindo1, W Brock1, G W Falk3, M I Canto3, J S Wang4, P G Iyer5, N J Shaheen6, W M Grady7, J A Abrams8, P N Thota9, K K Guda10, A Chak1,10.   

Abstract

Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC). Based on striking aggregation of breast cancer and BE/EAC within families as well as shared risk factors and molecular mechanisms of carcinogenesis, we hypothesized that BE may be associated with breast cancer. Pedigree analysis of families identified prospectively at multiple academic centers as part of the Familial Barrett's Esophagus Consortium (FBEC) was reviewed and families with aggregation of BE/EAC and breast cancer are reported. Additionally, using a matched case-control study design, we compared newly diagnosed BE cases in Caucasian females with breast cancer (cases) to Caucasian females without breast cancer (controls) who had undergone upper endoscopy (EGD). Two familial pedigrees, meeting a stringent inclusion criterion, manifested familial aggregation of BE/EAC and breast cancer in an autosomal dominant inheritance pattern with incomplete penetrance. From January 2008 to October 2016, 2812 breast cancer patient charts were identified, of which 213 were Caucasian females who underwent EGD. Six of 213 (2.82%) patients with breast cancer had pathology-confirmed BE, compared to 1 of 241 (0.41%) controls (P-value < 0.05). Selected families with BE/EAC show segregation of breast cancer. A breast cancer diagnosis is marginally associated with BE. We postulate a common susceptibility between BE/EAC and breast cancer.

Entities:  

Mesh:

Year:  2018        PMID: 29528378      PMCID: PMC6005759          DOI: 10.1093/dote/doy007

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  62 in total

Review 1.  The IGF system and breast cancer.

Authors:  D Sachdev; D Yee
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

Review 2.  Barrett's esophagus, esophageal and esophagogastric junction adenocarcinomas: the role of diet.

Authors:  A De Ceglie; D A Fisher; R Filiberti; S Blanchi; M Conio
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-01       Impact factor: 2.947

3.  Dietary consumption of meat, fat, animal products and advanced glycation end-products and the risk of Barrett's oesophagus.

Authors:  L Jiao; J R Kramer; L Chen; M Rugge; P Parente; G Verstovsek; A Alsarraj; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

4.  Statin use is associated with a decreased risk of Barrett's esophagus.

Authors:  Theresa Nguyen; Natalia Khalaf; David Ramsey; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2014-05-02       Impact factor: 22.682

5.  Transcriptional consequences of genomic structural aberrations in breast cancer.

Authors:  Koichiro Inaki; Axel M Hillmer; Leena Ukil; Fei Yao; Xing Yi Woo; Leah A Vardy; Kelson Folkvard Braaten Zawack; Charlie Wah Heng Lee; Pramila Nuwantha Ariyaratne; Yang Sun Chan; Kartiki Vasant Desai; Jonas Bergh; Per Hall; Thomas Choudary Putti; Wai Loon Ong; Atif Shahab; Valere Cacheux-Rataboul; Radha Krishna Murthy Karuturi; Wing-Kin Sung; Xiaoan Ruan; Guillaume Bourque; Yijun Ruan; Edison T Liu
Journal:  Genome Res       Date:  2011-04-05       Impact factor: 9.043

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Association of visceral adiposity with oesophageal and junctional adenocarcinomas.

Authors:  P Beddy; J Howard; C McMahon; M Knox; C de Blacam; N Ravi; J V Reynolds; M T Keogan
Journal:  Br J Surg       Date:  2010-07       Impact factor: 6.939

8.  Is chemotherapy associated with development of Barrett's esophagus?

Authors:  F T Peters; D T Sleijfer; G W van Imhoff; J H Kleibeuker
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

9.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

10.  Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.

Authors:  M Lindblad; L A García Rodríguez; E Chandanos; J Lagergren
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.